Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Prosthetics
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:PODD
- CUSIP: 45784P10
- Web: www.insulet.com
Capitalization:- Market Cap: $3.31869 billion
- Outstanding Shares: 58,059,000
Average Prices:- 50 Day Moving Avg: $56.08
- 200 Day Moving Avg: $47.79
- 52 Week Range: $30.69 - $59.99
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -337.82
- P/E Growth: -4.57
Sales & Book Value:- Annual Revenue: $409.92 million
- Price / Sales: 8.13
- Book Value: $1.12 per share
- Price / Book: 51.28
Profitability:- EBIDTA: $9.31 million
- Net Margins: -7.30%
- Return on Equity: -46.74%
- Return on Assets: -6.61%
Debt:- Debt-to-Equity Ratio: 5.27%
- Current Ratio: 7.06%
- Quick Ratio: 6.35%
Misc:- Average Volume: 369,975 shs.
- Beta: 1.51
- Short Ratio: 11.44
Frequently Asked Questions for Insulet Corporation (NASDAQ:PODD)
What is Insulet Corporation's stock symbol?
Insulet Corporation trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet Corporation's earnings last quarter?
Insulet Corporation (NASDAQ:PODD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $110 million for the quarter, compared to analyst estimates of $106.23 million. Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The firm's revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.08) EPS. View Insulet Corporation's Earnings History.
When will Insulet Corporation make its next earnings announcement?
Where is Insulet Corporation's stock going? Where will Insulet Corporation's stock price be in 2017?
15 equities research analysts have issued 1-year price objectives for Insulet Corporation's stock. Their forecasts range from $38.00 to $65.00. On average, they expect Insulet Corporation's share price to reach $51.08 in the next twelve months. View Analyst Ratings for Insulet Corporation.
What are analysts saying about Insulet Corporation stock?
Here are some recent quotes from research analysts about Insulet Corporation stock:
- 1. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
- 2. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (7/20/2017)
- 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
- 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)
Who are some of Insulet Corporation's key competitors?
Some companies that are related to Insulet Corporation include Ionis Pharmaceuticals (IONS), TESARO (TSRO), Dr. Reddy's Laboratories Ltd (RDY), BIOVERATIV INC (BIVV), Icon Plc (ICLR), DexCom (DXCM), bluebird bio (BLUE), Envision Healthcare Corporation (EVHC), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Neurocrine Biosciences (NBIX), Galapagos NV (GLPG), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), Valeant Pharmaceuticals International (VRX), athenahealth (ATHN), Hill-Rom Holdings (HRC) and PRA Health Sciences (PRAH).
Who are Insulet Corporation's key executives?
Insulet Corporation's management team includes the folowing people:
- Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer
- Shacey Petrovic, President, Chief Operating Officer
- Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer
- Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development
- David Colleran J.D., Senior Vice President, General Counsel, Secretary
- Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering
- Charles Alpuche, Senior Vice President - Global Manufacturing and Operations
- Michael Spears, Senior Vice President - Quality and Regulatory Affairs
- Bret Christensen, Chief Commercial Officer
- Jessica Hopfield Ph.D., Lead Independent Director
Who owns Insulet Corporation stock?
Insulet Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Capital Research Global Investors (10.13%), Vanguard Group Inc. (8.04%), BlackRock Inc. (6.90%), Frontier Capital Management Co. LLC (3.12%) and Fred Alger Management Inc. (2.18%). Company insiders that own Insulet Corporation stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet Corporation.
Who sold Insulet Corporation stock? Who is selling Insulet Corporation stock?
Insulet Corporation's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, BlackRock Inc., Rainier Investment Management LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., JPMorgan Chase & Co., Federated Investors Inc. PA and Fiera Capital Corp. Company insiders that have sold Insulet Corporation stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet Corporation.
Who bought Insulet Corporation stock? Who is buying Insulet Corporation stock?
Insulet Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Marshall Wace North America L.P., Capital Research Global Investors, Vanguard Group Inc., State Street Corp and Delta Lloyd Asset Management N.V.. Company insiders that have bought Insulet Corporation stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet Corporation.
How do I buy Insulet Corporation stock?
Shares of Insulet Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet Corporation's stock price today?
One share of Insulet Corporation stock can currently be purchased for approximately $57.43.
MarketBeat Community Rating for Insulet Corporation (NASDAQ PODD)MarketBeat's community ratings are surveys of what our community members think about Insulet Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Insulet Corporation (NASDAQ:PODD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $51.08 (11.06% downside) |
Analysts' Ratings History for Insulet Corporation (NASDAQ:PODD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/15/2017 | Barclays PLC | Initiated Coverage | Overweight -> Overweight | $65.00 | Low |  |
| 8/9/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $48.00 -> $58.00 | Low | |
| 8/4/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Hold | $55.00 | Low | |
| 8/4/2017 | Northland Securities | Reiterated Rating | Buy | | Low | |
| 8/4/2017 | Cowen and Company | Reiterated Rating | Outperform | $52.00 -> $63.00 | High | |
| 7/17/2017 | BTIG Research | Downgrade | Buy -> Neutral | | Medium | |
| 7/11/2017 | Canaccord Genuity | Reiterated Rating | Hold | $42.00 -> $50.00 | Low | |
| 5/25/2017 | William Blair | Reiterated Rating | Outperform -> Outperform | | Low | |
| 5/22/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight -> Overweight | $47.00 | Low | |
| 5/14/2017 | B. Riley | Reiterated Rating | Neutral | $44.00 | Low | |
| 2/28/2017 | Wedbush | Boost Price Target | Outperform -> Outperform | $48.00 -> $50.00 | N/A | |
| 2/27/2017 | Feltl & Co. | Downgrade | Buy -> Hold | | N/A | |
| 1/6/2017 | Robert W. Baird | Upgrade | Neutral -> Outperform | $39.00 -> $47.00 | N/A | |
| 11/17/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $38.00 | N/A | |
| 11/7/2016 | Leerink Swann | Reiterated Rating | Outperform | $55.00 -> $50.00 | N/A | |
| 5/16/2016 | Sterne Agee CRT | Reiterated Rating | Neutral | | N/A | |
| 2/26/2016 | Benchmark Co. | Upgrade | Hold -> Buy | $30.00 -> $40.00 | N/A | |
| 11/2/2015 | Morgan Stanley | Initiated Coverage | Equal -> Equal Weight | $32.00 | N/A | |
(Data available from 9/23/2015 forward)
Earnings History for Insulet Corporation (NASDAQ:PODD)Earnings History by Quarter for Insulet Corporation (NASDAQ PODD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | | | | | | | |
| 8/3/2017 | Q2 2017 | ($0.13) | ($0.13) | $106.23 million | $110.00 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.16) | ($0.17) | $97.73 million | $101.70 million | View | Listen | |
| 2/27/2017 | Q416 | ($0.05) | ($0.16) | $100.61 million | $103.58 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.09) | ($0.05) | $89.75 million | $94.90 million | View | N/A | |
| 8/3/2016 | Q216 | ($0.17) | ($0.08) | $81.10 million | $87.30 million | View | N/A | |
| 4/28/2016 | Q116 | ($0.19) | ($0.19) | $79.06 million | $81.21 million | View | Listen | |
| 2/25/2016 | Q415 | ($0.26) | ($0.48) | $91.89 million | $100.10 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.26) | ($0.33) | $83.56 million | $87.30 million | View | Listen | |
| 8/12/2015 | Q215 | ($0.13) | ($0.27) | $70.32 million | $75.60 million | View | Listen | |
| 4/30/2015 | Q115 | ($0.10) | ($0.21) | $68.20 million | $61.20 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.04) | ($0.10) | $73.52 million | $72.60 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.08) | ($0.06) | $72.94 million | $72.00 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.06) | ($0.11) | $68.47 million | $69.20 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.09) | ($0.04) | $67.94 million | $68.53 million | View | N/A | |
| 11/7/2013 | Q313 | ($0.16) | ($0.39) | $62.01 million | $61.10 million | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.19) | ($0.20) | $60.47 million | $60.09 million | View | N/A | |
| 5/6/2013 | Q1 2013 | ($0.21) | ($0.20) | $57.26 million | $57.40 million | View | N/A | |
| 2/27/2013 | Q4 2012 | ($0.21) | ($0.21) | $59.12 million | $57.80 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.22) | ($0.26) | $54.93 million | $54.80 million | View | N/A | |
| 8/8/2012 | | ($0.25) | ($0.30) | | | View | N/A | |
| 5/9/2012 | | ($0.28) | ($0.31) | | | View | N/A | |
| 2/9/2012 | | ($0.26) | ($0.30) | | | View | N/A | |
| 11/3/2011 | | ($0.25) | ($0.29) | | | View | N/A | |
| 8/2/2011 | | ($0.21) | ($0.42) | | | View | N/A | |
| 5/9/2011 | | ($0.22) | ($0.22) | | | View | N/A | |
| 2/15/2011 | | ($0.26) | ($0.50) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Insulet Corporation (NASDAQ:PODD)2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.09)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 8 | ($0.23) | ($0.10) | ($0.15) |
| Q2 2017 | 8 | ($0.16) | ($0.04) | ($0.12) |
| Q3 2017 | 8 | ($0.13) | ($0.02) | ($0.09) |
| Q4 2017 | 8 | ($0.11) | ($0.02) | ($0.09) |
| Q1 2018 | 5 | ($0.11) | $0.02 | ($0.06) |
| Q2 2018 | 5 | ($0.11) | $0.05 | ($0.02) |
| Q3 2018 | 4 | ($0.10) | $0.06 | $0.00 |
| Q4 2018 | 4 | ($0.09) | $0.06 | ($0.01) |
(Data provided by Zacks Investment Research)
Dividend History for Insulet Corporation (NASDAQ:PODD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Insulet Corporation (NASDAQ:PODD)Insider Ownership Percentage: 1.90%
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/6/2017 | Charles Alpuche | EVP | Buy | 2,500 | $58.08 | $145,200.00 | |
| 5/16/2017 | Michael P. Spears | SVP | Buy | 2,500 | $40.59 | $101,475.00 | |
| 5/11/2017 | Bradley A. Thomas | EVP | Buy | 3,000 | $38.69 | $116,070.00 | |
| 5/11/2017 | Jessica Hopfield | Director | Buy | 2,580 | $38.68 | $99,794.40 | |
| 5/1/2017 | David A. Lemoine | Director | Sell | 1,524 | $43.40 | $66,141.60 | |
| 3/13/2017 | Regina O. Sommer | Director | Sell | 40,000 | $45.00 | $1,800,000.00 | |
| 3/6/2017 | David A. Lemoine | Director | Sell | 1,282 | $45.15 | $57,882.30 | |
| 3/2/2017 | Joseph S. Zakrzewski | Director | Sell | 40,000 | $46.86 | $1,874,400.00 | |
| 12/9/2016 | Charles Alpuche | SVP | Buy | 6,600 | $37.70 | $248,820.00 | |
| 12/2/2016 | Patrick J. Sullivan | CEO | Buy | 40,000 | $33.89 | $1,355,600.00 | |
| 12/1/2016 | Bradley A. Thomas | EVP | Buy | 3,100 | $32.45 | $100,595.00 | |
| 5/25/2016 | Regina O Sommer | Director | Sell | 8,019 | $30.42 | $243,937.98 | |
| 5/18/2016 | Patrick J Sullivan | CEO | Buy | 45,000 | $27.00 | $1,215,000.00 | |
| 5/13/2016 | Bradley A Thomas | EVP | Buy | 2,975 | $26.63 | $79,224.25 | |
| 5/5/2016 | Bradley A Thomas | EVP | Buy | 1,656 | $30.13 | $49,895.28 | |
| 3/10/2016 | Daniel J Levangie | Insider | Sell | 12,299 | $30.89 | $379,916.11 | |
| 3/7/2016 | Daniel J Levangie | Insider | Sell | 7,663 | $31.15 | $238,702.45 | |
| 3/2/2016 | Jessica Hopfield | Director | Buy | 3,230 | $30.91 | $99,839.30 | |
| 6/5/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $29.39 | $293,900.00 | |
| 5/28/2015 | Patrick J Sullivan | CEO | Buy | 20,000 | $27.91 | $558,200.00 | |
| 5/15/2015 | Timothy J Scannell | Director | Buy | 3,500 | $27.05 | $94,675.00 | |
| 5/5/2015 | Bradley A Thomas | EVP | Buy | 1,000 | $27.26 | $27,260.00 | |
| 5/5/2015 | Patrick Ryan | COO | Buy | 3,669 | $26.99 | $99,026.31 | |
| 4/2/2015 | R Anthony Diehl | General Counsel | Sell | 3,372 | $30.96 | $104,397.12 | |
| 3/9/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $31.93 | $319,300.00 | |
| 3/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | |
| 2/12/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | |
| 1/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $46.08 | $184,320.00 | |
| 11/3/2014 | Charles T Liamos | Director | Sell | 4,000 | $42.95 | $171,800.00 | |
| 10/1/2014 | Charles T Liamos | Director | Sell | 4,000 | $36.58 | $146,320.00 | |
| 10/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $36.59 | $45,737.50 | |
| 9/10/2014 | Charles T Liamos | Director | Sell | 4,000 | $35.17 | $140,680.00 | |
| 9/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.30 | $726,000.00 | |
| 8/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $34.23 | $684,600.00 | |
| 7/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $40.52 | $810,400.00 | |
| 7/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $39.65 | $49,562.50 | |
| 6/11/2014 | R Anthony Diehl | General Counsel | Sell | 17,871 | $37.09 | $662,835.39 | |
| 6/9/2014 | Peter Devlin | Insider | Sell | 12,314 | $37.10 | $456,849.40 | |
| 4/8/2014 | Peter Devlin | Insider | Sell | 30,000 | $41.25 | $1,237,500.00 | |
| 4/3/2014 | R Anthony Diehl | General Counsel | Sell | 4,617 | $48.67 | $224,709.39 | |
| 3/6/2014 | R Anthony Diehl | General Counsel | Sell | 12,458 | $49.28 | $613,930.24 | |
| 3/6/2014 | Tracey Haas Wielinski | VP | Sell | 8,275 | $49.21 | $407,212.75 | |
| 2/3/2014 | Charles Liamos | Director | Sell | 11,037 | $42.93 | $473,818.41 | |
| 2/3/2014 | Duane Desisto | CEO | Sell | 20,000 | $42.95 | $859,000.00 | |
| 2/3/2014 | Peter Devlin | Insider | Sell | 30,000 | $42.82 | $1,284,600.00 | |
| 1/3/2014 | Charles Liamos | COO | Sell | 86,000 | $36.02 | $3,097,720.00 | |
| 1/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.07 | $721,400.00 | |
| 12/3/2013 | Charles Liamos | COO | Sell | 63,808 | $36.26 | $2,313,678.08 | |
| 11/18/2013 | Charles Liamos | COO | Sell | 80,000 | $35.60 | $2,848,000.00 | |
| 9/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $33.38 | $667,600.00 | |
| 8/29/2013 | Sally Crawford | Director | Sell | 9,000 | $33.42 | $300,780.00 | |
| 8/15/2013 | Regina Sommer | Director | Sell | 5,000 | $33.32 | $166,600.00 | |
| 8/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.85 | $637,000.00 | |
| 7/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.51 | $630,200.00 | |
| 7/1/2013 | Peter Devlin | Insider | Sell | 30,000 | $31.48 | $944,400.00 | |
| 6/14/2013 | Sally Crawford | Director | Sell | 31,000 | $30.47 | $944,570.00 | |
| 6/10/2013 | R Anthony Diehl | General Counsel | Sell | 38,455 | $30.50 | $1,172,877.50 | |
| 6/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $29.76 | $595,200.00 | |
| 12/3/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.92 | $219,200.00 | |
| 11/1/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.49 | $214,900.00 | |
| 9/4/2012 | Brian K Roberts | CFO | Sell | 10,000 | $20.78 | $207,800.00 | |
| 9/4/2012 | Duane Desisto | CEO | Sell | 20,000 | $20.97 | $419,400.00 | |
| 9/4/2012 | Ruthann Depietro | VP | Sell | 1,000 | $20.90 | $20,900.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Insulet Corporation (NASDAQ:PODD)
Latest Headlines for Insulet Corporation (NASDAQ:PODD)
| Source: |
|
Insulet Corporation (PODD) Chart for Saturday, September, 23, 2017
